IMARC Group, a leading market research company, has released a report titled “Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. According to the report, The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.
Hemophilia is a genetic medical condition that impacts the blood clotting mechanism of the body. It causes abnormal blood clots, leading to excessive bleeding, easy bruising, and oozing after an injury, surgery, or dental procedure. It occurs due to a hereditary deficiency in coagulation factor that inhibits blood clotting by limiting the availability of necessary blood-clotting proteins. Its treatment primarily focuses on replacing the missing proteins and preventing potential complications. At present, hemophilia can be treated through medications, replacement therapy, and injections of a clotting factor or plasma across the globe.Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsampleHemophilia Market Trends and Drivers:The global hemophilia market is primarily driven by the increasing number of patients with hemophilia and a rise in genetic abnormalities across the globe. Additionally, the surging popularity of prophylactic treatment and the rising diagnosis rate of illness is positively influencing the market growth. Moreover, several favorable initiatives by governments of numerous countries to spread awareness about the benefits of early diagnosis and proper procedures for early screening of neonates have catalyzed market growth. Furthermore, several key players are focusing on introducing technologically advanced diagnostic tools and therapies to improve the effectiveness and precision of hemophilia treatment, thereby contributing to market growth. Other factors, including increasing funding for research and development (R&D) activities, the rapid expansion of specialized hemophilia treatment centers (HTCs), and rising demand for early diagnosis of hemophilia, are also anticipated to drive the market further.Report Segmentation:The report has segmented the market into the following categories:Breakup by Type: